More recently, two clinical trials demonstrated that modulation of the gut microbiome with fecal microbiome transplantation from donors receiving anti-PD-1 inhibitor immunotherapy who showed a complete response into patients with refractory metastatic melanoma was safe and capable of enhancing the efficacy of cancer therapies [24,25]. This evidence concerns the gene PDCD1 and cancer.